疫苗佐劑市場規模、佔有率和趨勢分析報告：按類型、應用、劑量、地區和細分市場分類，預測期為2026-2033年

Vaccine Adjuvants Market Size, Share & Trends Analysis Report By Type, By Application, By Administration, By Region, And Segment Forecasts, 2026 - 2033

出版日期: 2026年01月09日 | 出版商:

Grand View Research | 英文 120 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

疫苗佐劑市場概述

2025年全球疫苗佐劑市場規模估計為39.4億美元，預計2033年將達到59.6億美元。

預計從 2026 年到 2033 年，該市場將以 5.60% 的複合年成長率成長。推動該市場成長的因素包括：對有效疫苗的需求不斷成長，以對抗新興和再發感染疾病；以及癌症等慢性疾病的日益普及。

人們越來越認知到佐劑在增強免疫反應的效力、持續時間和廣度方面的作用，這推動了佐劑在預防性和治療性疫苗中的應用。免疫學和分子生物學的進步促成了新一代佐劑的開發，例如皂素佐劑和Toll樣受體（TLR）促效劑，這些佐劑能夠選擇性地靶向免疫通路，並具有更高的安全性和有效性。這些創新滿足了疫苗的迫切需求，即在降低抗原劑量的同時誘導強效的免疫反應，從而提高成本效益和擴充性。例如，Springer Nature於2025年8月在《藥物化學研究》（Medicinal Chemistry Research，第34卷，第1817-1832頁）上發表的一篇綜述指出，廣泛研究的皂素佐劑QS-21由約65%的QS-21-Api和35%的甲苯二構體組成。作者報告了該化合物生物合成的成功闡明，並比較了半合成法所得產率。具體而言，利用基因改造酵母生產的該化合物的重量比約為0.0012%，而天然來源的該化合物的重量比約為0.0032%，這凸顯了其在增強抗原特異性抗體和細胞免疫反應中的作用。

此外，各國政府、非政府組織和製藥公司不斷增加對疫苗研發的投資，也推動了市場成長。在全球範圍內，尤其是在中低收入國家，擴大先進佐劑疫苗使用的努力發揮核心作用。例如，2024年6月，全球疫苗免疫聯盟（Gavi）核准了其新的五年策略－Gavi 6.0。該策略承諾在2026年至2030年間，支持為超過5億名兒童和青少年接種疫苗，預防800萬至900萬人死亡（其中150萬人死於人類乳突病毒(HPV)疫苗），並擴大20多種疾病疫苗的覆蓋範圍。該策略尤其關注登革熱等氣候敏感型疾病，以及一種計劃在戰略週期結束前推出的新型結核病疫苗。這些努力，加上在 COVID-19 和其他感染疾病爆發後加強的疫情防範措施，進一步強調了快速開發和部署佐劑疫苗的必要性。

市場也受益於有利的監管支持，包括加快核准流程和優先資助關鍵疫苗技術。然而，高昂的研發成本、嚴格的監管要求以及廣泛的臨床檢驗需求等挑戰仍然是主要障礙。儘管有這些限制，但基於佐劑的疫苗開發平臺的不斷擴展，以及全球對疫苗接種在公共衛生中作用的認知不斷提高，預計將推動疫苗佐劑產業在預測期內持續成長。

區域展望
疫苗佐劑市場區域分析：要點
北美洲
- 美國
- 加拿大
- 墨西哥
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 丹麥
- 瑞典
- 挪威
亞太地區
- 日本
- 中國
- 印度
- 澳洲
- 泰國
- 韓國
拉丁美洲
- 巴西
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國
- 科威特

第8章競爭情勢

對主要市場參與企業近期趨勢和影響的分析
市場參與企業分類
- GlaxoSmithKline plc
- Novartis/CSL Limited
- Agenus Inc
- Adjuvance Technologies, Inc
- Novavax Inc.
- SPI Pharma
- Invivogen
- Avanti Polar Lipids
- Brentagg

簡介目錄圖表

Product Code: GVR-1-68038-612-7

Vaccine Adjuvants Market Summary

The global vaccine adjuvants market size was estimated at USD 3.94 billion in 2025 and is projected to reach USD 5.96 billion by 2033, growing at a CAGR of 5.60% from 2026 to 2033. The growth of the market is driven by the increasing demand for effective vaccines to combat emerging and re-emerging infectious diseases, as well as the rising prevalence of chronic conditions such as cancer.

The growing recognition of adjuvants' role in enhancing the efficacy, durability, and breadth of immune responses is propelling their adoption across both prophylactic and therapeutic vaccines. Advancements in immunology and molecular biology have enabled the development of next-generation adjuvants, including saponin-based adjuvants and toll-like receptor (TLR) agonists, which selectively target immune pathways and deliver improved safety and efficacy profiles. These innovations address the unmet need for vaccines capable of eliciting strong immune responses with reduced antigen doses, improving cost efficiency and scalability. For instance, in August 2025, Springer Nature published a review in Medicinal Chemistry Research (Volume 34, pages 1817-1832) highlighting that the widely studied saponin adjuvant QS-21 consists of approximately 65 percent QS-21-Api and 35 percent QS-21-Xyl isomers and has been incorporated into licensed vaccines such as Shingrix, Mosquirix, and Arexvy, with the authors reporting successful biosynthetic elucidation and comparing semi-synthetic yields, including engineered yeast production at roughly 0.0012 percent weight-by-weight versus about 0.0032 percent from natural sources, underscoring its role in enhancing antigen-specific antibody and cellular immune responses.

In addition, rising investments in vaccine research and development by governments, non-governmental organizations, and pharmaceutical companies are accelerating market growth. Global initiatives are playing a central role in expanding access to advanced adjuvanted vaccines, particularly in low- and middle-income countries. For instance, in June 2024, Gavi, the Vaccine Alliance approved its new five-year strategy, Gavi 6.0, committing to support countries in vaccinating more than 500 million additional children and adolescents, projecting the prevention of 8-9 million deaths, including 1.5 million through HPV vaccination, and expanding access to vaccines targeting 20+ diseases during the 2026-2030 period, with an added focus on climate-sensitive diseases such as dengue and the anticipated rollout of a new tuberculosis vaccine by the end of the strategy cycle. These initiatives, alongside heightened pandemic preparedness following COVID-19 and other outbreaks, have reinforced the need for adjuvant-enhanced vaccines that enable rapid development and deployment.

The market also benefits from favorable regulatory support, including expedited approval pathways and targeted funding for critical vaccine technologies. However, challenges such as high development costs, stringent regulatory requirements, and the need for extensive clinical validation remain key barriers. Despite these constraints, the expanding pipeline of adjuvant-based vaccines and growing global awareness of immunization's role in public health continue to position the vaccine adjuvants industry for sustained growth over the forecast period.

Global Vaccine Adjuvants Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global vaccine adjuvants market report based on type, application, administration, and region:

Type Outlook (Revenue, USD Million, 2021 - 2033)
Pathogen
Adjuvant emulsion
Particulate
Combination
Others
Application Outlook (Revenue, USD Million, 2021 - 2033)
Infectious diseases
Cancer
Others
Administration Outlook (Revenue, USD Million, 2021 - 2033)
Oral
Intradermal
Intranasal
Intramuscular
Others
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- Thailand
- South Korea
Latin America
- Brazil
- Argentina
Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
- 1.1.1. Type
- 1.1.2. Application
- 1.1.3. Administration
- 1.1.4. Regional scope
- 1.1.5. Estimates and forecast timeline.
1.2. Research Methodology
1.3. Information Procurement
- 1.3.1. Purchased database.
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Type outlook
- 2.2.2. Application outlook
- 2.2.3. Administration outlook
- 2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Vaccine Adjuvants Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
- 3.3.1. Market driver analysis
- 3.3.2. Market restraint analysis
3.4. Vaccine Adjuvants Market Analysis Tools
- 3.4.1. Industry Analysis - Porter's
  - 3.4.1.1. Supplier power
  - 3.4.1.2. Buyer power
  - 3.4.1.3. Substitution threat
  - 3.4.1.4. Threat of new entrant
  - 3.4.1.5. Competitive rivalry
- 3.4.2. PESTEL Analysis
  - 3.4.2.1. Political landscape
  - 3.4.2.2. Technological landscape
  - 3.4.2.3. Economic landscape

Chapter 4. Vaccine Adjuvants: Type Estimates & Trend Analysis

4.1. Vaccine Adjuvants Market: Key Takeaways
4.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
4.3. Pathogen
- 4.3.1. Pathogen market estimates and forecasts, 2021 to 2033 (USD Million)
4.4. Adjuvant emulsion
- 4.4.1. Adjuvant emulsion market estimates and forecasts, 2021 to 2033 (USD Million)
4.5. Particulate
- 4.5.1. Particulate market estimates and forecasts, 2021 to 2033 (USD Million)
4.6. Combination
- 4.6.1. Combination market estimates and forecasts, 2021 to 2033 (USD Million)
4.7. Others
- 4.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 5. Vaccine Adjuvants: Application Estimates & Trend Analysis

5.1. Vaccine Adjuvants Market: Key Takeaways
5.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
5.3. Infectious diseases
- 5.3.1. Infectious diseases market estimates and forecasts, 2021 to 2033 (USD Million)
5.4. Cancer
- 5.4.1. Cancer market estimates and forecasts, 2021 to 2033 (USD Million)
5.5. Others
- 5.5.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 6. Vaccine Adjuvants: Administration Estimates & Trend Analysis

6.1. Vaccine Adjuvants Market: Key Takeaways
6.2. Vaccine Adjuvants Market: Movement & Market Share Analysis, 2025 & 2033
6.3. Oral
- 6.3.1. Oral market estimates and forecasts, 2021 to 2033 (USD Million)
6.4. Intradermal
- 6.4.1. Intradermal market estimates and forecasts, 2021 to 2033 (USD Million)
6.5. Intranasal
- 6.5.1. Intranasal market estimates and forecasts, 2021 to 2033 (USD Million)
6.6. Intramuscular
- 6.6.1. Intramuscular market estimates and forecasts, 2021 to 2033 (USD Million)
6.7. Others
- 6.7.1. Others market estimates and forecasts, 2021 to 2033 (USD Million)

Chapter 7. Vaccine Adjuvants Market: Regional Estimates & Trend Analysis

7.1. Regional Outlook
7.2. Vaccine Adjuvants Market by Region: Key Takeaways
7.3. North America
- 7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.2. U.S.
  - 7.3.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.3. Canada
  - 7.3.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.3.4. Mexico
  - 7.3.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
7.4. Europe
- 7.4.1. UK
  - 7.4.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.2. Germany
  - 7.4.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.3. France
  - 7.4.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.4. Italy
  - 7.4.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.5. Spain
  - 7.4.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.6. Denmark
  - 7.4.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.7. Sweden
  - 7.4.7.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.4.8. Norway
  - 7.4.8.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
7.5. Asia Pacific
- 7.5.1. Japan
  - 7.5.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.2. China
  - 7.5.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.3. India
  - 7.5.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.4. Australia
  - 7.5.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.5. Thailand
  - 7.5.5.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.5.6. South Korea
  - 7.5.6.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
7.6. Latin America
- 7.6.1. Brazil
  - 7.6.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.6.2. Argentina
  - 7.6.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
7.7. MEA
- 7.7.1. South Africa
  - 7.7.1.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.2. Saudi Arabia
  - 7.7.2.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.3. UAE
  - 7.7.3.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)
- 7.7.4. Kuwait
  - 7.7.4.1. Market estimates and forecasts, 2021 - 2033 (Revenue, USD Million)

Chapter 8. Competitive Landscape

8.1. Recent Developments & Impact Analysis, By Key Market Participants
8.2. Market Participant Categorization
- 8.2.1. GlaxoSmithKline plc
  - 8.2.1.1. Company overview
  - 8.2.1.2. Financial performance
  - 8.2.1.3. Product benchmarking
  - 8.2.1.4. Strategic initiatives
- 8.2.2. Novartis/CSL Limited
  - 8.2.2.1. Company overview
  - 8.2.2.2. Financial performance
  - 8.2.2.3. Product benchmarking
  - 8.2.2.4. Strategic initiatives
- 8.2.3. Agenus Inc
  - 8.2.3.1. Company overview
  - 8.2.3.2. Financial performance
  - 8.2.3.3. Product benchmarking
  - 8.2.3.4. Strategic initiatives
- 8.2.4. Adjuvance Technologies, Inc
  - 8.2.4.1. Company overview
  - 8.2.4.2. Financial performance
  - 8.2.4.3. Product benchmarking
  - 8.2.4.4. Strategic initiatives
- 8.2.5. Novavax Inc.
  - 8.2.5.1. Company overview
  - 8.2.5.2. Financial performance
  - 8.2.5.3. Product benchmarking
  - 8.2.5.4. Strategic initiatives
- 8.2.6. SPI Pharma
  - 8.2.6.1. Company overview
  - 8.2.6.2. Financial performance
  - 8.2.6.3. Product benchmarking
  - 8.2.6.4. Strategic initiatives
- 8.2.7. Invivogen
  - 8.2.7.1. Company overview
  - 8.2.7.2. Financial performance
  - 8.2.7.3. Product benchmarking
  - 8.2.7.4. Strategic initiatives
- 8.2.8. Avanti Polar Lipids
  - 8.2.8.1. Company overview
  - 8.2.8.2. Financial performance
  - 8.2.8.3. Product benchmarking
  - 8.2.8.4. Strategic initiatives
- 8.2.9. Brentagg
  - 8.2.9.1. Company overview
  - 8.2.9.2. Financial performance
  - 8.2.9.3. Product benchmarking
  - 8.2.9.4. Strategic initiatives

簡介目錄圖表

List of Tables

Table 1 List of Abbreviation
Table 2 North America Vaccine Adjuvants market, by type, 2021 - 2033 (USD Million)
Table 3 North America vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 4 North America vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 5 North America vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
Table 6 U.S. vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 7 U.S. vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 8 U.S. vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 9 Canada vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 10 Canada vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 11 Canada vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 12 Mexico vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 13 Mexico vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 14 Mexico vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 15 Europe vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 16 Europe vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 17 Europe vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 18 Europe vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
Table 19 Germany vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 20 Germany vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 21 Germany vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 22 UK vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 23 UK vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 24 UK vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 25 France vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 26 France vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 27 France vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 28 Italy vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 29 Italy vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 30 Italy vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 31 Spain vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 32 Spain vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 33 Spain vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 34 Denmark vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 35 Denmark vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 36 Denmark vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 37 Sweden vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 38 Sweden vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 39 Sweden vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 40 Norway vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 41 Norway vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 42 Norway vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 43 Asia Pacific vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 44 Asia Pacific vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 45 Asia Pacific vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 46 Asia Pacific vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
Table 47 Japan vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 48 Japan vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 49 Japan vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 50 China vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 51 China vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 52 China vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 53 India vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 54 India vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 55 India vaccine adjuvants market, by administration, (USD Million) 2021 - 2033
Table 56 Australia vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 57 Australia vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 58 Australia vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 59 Thailand vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 60 Thailand vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 61 Thailand vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 62 South Korea vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 63 South Korea vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 64 South Korea vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 65 Latin America vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 66 Latin America vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 67 Latin America vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 68 Latin America vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
Table 69 Brazil vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 70 Brazil vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 71 Brazil vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 72 Argentina vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 73 Argentina vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 74 Argentina vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 75 Middle East and Africa vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 76 Middle East and Africa vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 77 Middle East and Africa vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 78 Middle East and Africa vaccine adjuvants market, by region, 2021 - 2033 (USD Million)
Table 79 South Africa vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 80 South Africa vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 81 South Africa vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 82 Saudi Arabia vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 83 Saudi Arabia vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 84 Saudi Arabia vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 85 UAE vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 86 UAE vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 87 UAE vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)
Table 88 Kuwait vaccine adjuvants market, by type, 2021 - 2033 (USD Million)
Table 89 Kuwait vaccine adjuvants market, by application, 2021 - 2033 (USD Million)
Table 90 Kuwait vaccine adjuvants market, by administration, 2021 - 2033 (USD Million)